Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascend Wellness HoldingsAAWH -2.50%46 EV-to-EBITDA is 10.87 as of Jul. 28, 2026, which is 10% above its 10-year median of 9.88. GuruFocus rates AAWH with a GF Score™ of 46/100 and a GF Value™ of $0.73 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 742 Drug Manufacturers companies, Ascend Wellness Holdings ranks better than 57.14% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ascend Wellness Holdings's enterprise value is $647.8 Mil.
Ascend Wellness Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $59.6 Mil. Therefore, Ascend Wellness Holdings's EV-to-EBITDA for today is 10.87.
The historical rank and industry rank for Ascend Wellness Holdings's EV-to-EBITDA or its related term are showing as below:
AAWH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2405.99 Med: 9.88 Max: 950.53
Current: 10.87
During the past 7 years, the highest EV-to-EBITDA of Ascend Wellness Holdings was 950.53. The lowest was -2405.99. And the median was 9.88.
AAWH's EV-to-EBITDA is ranked better than 57.14% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.93
vs AAWH: 10.87
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ascend Wellness Holdings's PE Ratio (TTM) for today is calculated as:
Ascend Wellness Holdings's share price for today is $0.39.
Ascend Wellness Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.640.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ascend Wellness Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascend Wellness Holdings EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ascend Wellness Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ascend Wellness Holdings's EV-to-EBITDA falls into.
Ascend Wellness Holdings's current Enterprise Value is $647.8 Mil.
Ascend Wellness Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $59.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascend Wellness Holdings (AAWH) has a EV-to-EBITDA of 10.87 as of Jul. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ascend Wellness Holdings. This is 10% above median its historical median of 9.88. According to the industry distribution chart, Ascend Wellness Holdings ranks #318 out of 742 companies in the Drug Manufacturers industry, placing it in the top 42.9%.
Is Ascend Wellness Holdings' EV-to-EBITDA too high?
Ascend Wellness Holdings' current EV-to-EBITDA of 10.87 is 10% above median its 10-year median of 9.88. The Drug Manufacturers industry median EV-to-EBITDA is 12.93. Ascend Wellness Holdings' value of 10.87 is 15.9% below this industry median. Based on the distribution chart, Ascend Wellness Holdings ranks #318 out of 742 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ascend Wellness Holdings has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascend Wellness Holdings' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ascend Wellness Holdings ranks #318 out of 742 companies for EV-to-EBITDA. This puts Ascend Wellness Holdings in the upper half of its industry. The industry median EV-to-EBITDA is 12.93. Ascend Wellness Holdings' value of 10.87 is 15.9% below this benchmark. While the company's 10-year median is 9.88 vs. the industry median of 12.93, Ascend Wellness Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.93, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascend Wellness Holdings's current EV-to-EBITDA of 10.87 is 15.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ascend Wellness Holdings. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascend Wellness Holdings's current EV-to-EBITDA is 10.87, which is 10% above median its own 10-year median of 9.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascend Wellness Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ascend Wellness Holdings (AAWH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.73, compared to a current price of $0.39 — trading 46.6% below its estimated fair value. The current EV-to-EBITDA is 10.87, which is 10% above median its 10-year median of 9.88 and 15.9% below the Drug Manufacturers industry median of 12.93. Ascend Wellness Holdings' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ascend Wellness Holdings (AAWH), the current EV-to-EBITDA is 10.87 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascend Wellness Holdings (AAWH) Overvalued in 2026?
Based on GuruFocus' analysis, Ascend Wellness Holdings stock appears to be undervalued.
The current stock price of $0.39 is trading 46.6% below its estimated GF Value™ of $0.73.
GuruFocus considers Ascend Wellness Holdings to be Possible Value Trap.
Key valuation signals for AAWH:
EV-to-EBITDA: 10.87 (10% above median its 10-year median of 9.88)
GF Value™: $0.73 vs. price of $0.39 (46.6% below fair value)
Industry Position: 15.9% below the Drug Manufacturers median (#318 of 742)
No single metric tells the full story. See the AAWH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascend Wellness Holdings Inc is a vertically integrated multi-state operator focused on adult-use or near-term adult-use cannabis states in limited licenses markets. The company's core business is the cultivation, manufacturing, and distribution of cannabis consumer packaged goods, which it sells through company-owned retail stores and third-party licensed cannabis retail stores. It generates maximum revenue from the retail product segment.
46GF Score
Get the complete analysis for AAWH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AAWH has been successfully added to your 
